Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors Via Tumor-Derived Exosome and T Cell Modulation

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Feb 25

PMID 35205655

Authors

Jacob W Greenberg

Hogyoung Kim

Miae Ahn

Ahmed A Moustafa

He Zhou

Pedro C Barata

A Hamid Boulares

Asim B Abdel-Mageed

Louis S Krane

Affiliations

Soon will be listed here.

Abstract

Background: Tyrosine kinase inhibitors (TKI) were initially demonstrated as an efficacious treatment for renal cell carcinoma (RCC). However, after a median treatment length of 14 months, a vast majority of patients develop resistance. This study analyzed a combination therapy of tipifarnib (Tipi) + sunitinib that targeted exosome-conferred drug resistance.

Methods: 786-O, 786-O-SR (sunitinib resistant), A498, A498-SR, Caki-2, Caki-2-SR, and 293T cells were cultured. Exosomes were collected using differential ultracentrifugation. Cell proliferation, Jurkat T cell immune assay, and immunoblot analysis were used for downstream analysis.

Results: SR exosomes treatment displayed a cytotoxic effect on immune cells. This cytotoxic effect was associated with increased expression of PD-L1 on SR exosomes when compared to sunitinib-sensitive (SS) exosomes. Additionally, Tipi treatment downregulated PD-L1 expression on exosomes derived from SR cell lines. Tipi's ability to downregulate PD-L1 in exosomes has a significant application within patients. Exosomes collected from patients with RCC showed increased PD-L1 expression over subjects without RCC. Next, exosome concentrations were then compared after Tipi treatment, with all SS cell lines displaying an even greater reduction. On immunoblot assay, 293T cells showed a dose-dependent increase in Alix with no change in either nSMase or Rab27a. Conversely, all the SS and SR cell lines displayed a decrease in all three markers. After a cell proliferation employed a 48-h treatment on all SS and SR cell lines, the drug combination displayed synergistic ability to decrease tumor growth.

Conclusions: Tipifarnib attenuates both the exosome endosomal sorting complex required for endosomal sorting complex required for transport (ESCRT)-dependent and ESCRT-independent pathways, thereby blocking exosome biogenesis and secretion as well as downregulating PD-L1 on SS and SR cells.

Citing Articles

Extracellular vesicles in tumor immunity: mechanisms and novel insights.

Kuang L, Wu L, Li Y Mol Cancer. 2025; 24(1):45.

PMID: 39953480 PMC: 11829561. DOI: 10.1186/s12943-025-02233-w.

Development of 6-amido-4-aminoisoindolyn-1,3-diones as p70S6K1 inhibitors and potential breast cancer therapeutics.

Thornton A, Komati R, Kim H, Myers J, Petty K, Sam R Front Mol Biosci. 2025; 11():1481912.

PMID: 39749216 PMC: 11694070. DOI: 10.3389/fmolb.2024.1481912.

Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?.

Healy F, Turner A, Marensi V, MacEwan D Front Pharmacol. 2024; 15:1441938.

PMID: 39372214 PMC: 11450236. DOI: 10.3389/fphar.2024.1441938.

Exosome in renal cell carcinoma progression and implications for targeted therapy.

Li X, Xiao W, Yang H, Zhang X Front Oncol. 2024; 14:1458616.

PMID: 39296981 PMC: 11408481. DOI: 10.3389/fonc.2024.1458616.

GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.

Huang S, Liu J, Hu J, Hou Y, Hu M, Zhang B J Cell Mol Med. 2024; 28(8):e18290.

PMID: 38588015 PMC: 11000813. DOI: 10.1111/jcmm.18290.

References

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499. PMC: 5931375. DOI: 10.1038/nature22396. View

Das T, Sa G, Paszkiewicz-Kozik E, Hilston C, Molto L, Rayman P . Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways. J Immunol. 2008; 180(7):4687-96. DOI: 10.4049/jimmunol.180.7.4687. View

Xie F, Zhou X, Fang M, Li H, Su P, Tu Y . Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy. Adv Sci (Weinh). 2019; 6(24):1901779. PMC: 6918121. DOI: 10.1002/advs.201901779. View

Teixeira A, Dias F, Gomes M, Fernandes M, Medeiros R . Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?. J Kidney Cancer VHL. 2017; 1(8):84-98. PMC: 5345530. DOI: 10.15586/jkcvhl.2014.19. View

Qu Y, Tan H, Chan Y, Jiang H, Wang N, Wang D . The functional role of long noncoding RNA in resistance to anticancer treatment. Ther Adv Med Oncol. 2020; 12:1758835920927850. PMC: 7268113. DOI: 10.1177/1758835920927850. View

Li X, Corbett A, Taatizadeh E, Tasnim N, Little J, Garnis C . Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019; 3(1):011503. PMC: 6481742. DOI: 10.1063/1.5087122. View

Vautrot V, Bentayeb H, Causse S, Garrido C, Gobbo J . Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. Cancers (Basel). 2021; 13(18). PMC: 8467727. DOI: 10.3390/cancers13184537. View

Motzer R, Escudier B, Gannon A, Figlin R . Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist. 2016; 22(1):41-52. PMC: 5313263. DOI: 10.1634/theoncologist.2016-0197. View

Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A . Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021; 39(11):1497-1518.e11. PMC: 8599450. DOI: 10.1016/j.ccell.2021.10.001. View

10.

Alonso-Alonso R, Mondejar R, Martinez N, Garcia-Diaz N, Perez C, Merino D . Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. Sci Rep. 2020; 10(1):6721. PMC: 7174413. DOI: 10.1038/s41598-020-63434-5. View

11.

Hanna G, Guenette J, Chau N, Sayehli C, Wilhelm C, Metcalf R . Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020; 126(17):3972-3981. PMC: 8266417. DOI: 10.1002/cncr.33036. View

12.

Ho A, Brana I, Haddad R, Bauman J, Bible K, Oosting S . Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. J Clin Oncol. 2021; 39(17):1856-1864. PMC: 8189627. DOI: 10.1200/JCO.20.02903. View

13.

Yang Y, Li C, Chan L, Wei Y, Hsu J, Xia W . Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018; 28(8):862-864. PMC: 6082826. DOI: 10.1038/s41422-018-0060-4. View

14.

Del Re M, van Schaik R, Fogli S, Mathijssen R, Cucchiara F, Capuano A . Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Biochim Biophys Acta Rev Cancer. 2020; 1875(1):188463. DOI: 10.1016/j.bbcan.2020.188463. View

15.

Morais C . Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL. 2017; 1(1):1-11. PMC: 5345511. DOI: 10.15586/jkcvhl.2014.7. View

16.

Morrissey S, Yan J . Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy. Trends Cancer. 2020; 6(7):550-558. PMC: 7330176. DOI: 10.1016/j.trecan.2020.03.002. View

17.

Ahn S, Nguyen S, Petroff M . Exploring the Origin and Antigenic Specificity of Maternal Regulatory T Cells in Pregnancy. Front Immunol. 2020; 11:1302. PMC: 7330120. DOI: 10.3389/fimmu.2020.01302. View

18.

Zheng J, Sun X, Chen J, Jiang F, Li W, Xie S . [Mechanism of immune escape in renal cell carcinoma]. Zhonghua Zhong Liu Za Zhi. 2002; 24(1):24-6. View

19.

Muus P, Langemeijer S, van Bijnen S, Blijlevens N, de Witte T . A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia. Leuk Res. 2021; 105:106573. DOI: 10.1016/j.leukres.2021.106573. View

20.

Wang J, Zeng H, Zhang H, Han Y . The role of exosomal PD-L1 in tumor immunotherapy. Transl Oncol. 2021; 14(5):101047. PMC: 7921878. DOI: 10.1016/j.tranon.2021.101047. View